Medical System Network Co Ltd

Medical System Network Co Ltd has a liquidity position that is relatively constrained, with a current ratio of 0.93 and a debt-to-equity ratio of 1.83, indicating a higher reliance on debt financing. The company's price-to-book ratio of 0.91 and price-to-tangible-book ratio of 0.91 suggest that the market values the company close to its tangible book value. The company's free cash flow of 1.27 billion JPY and operating cash flow of 4.46 billion JPY provide some buffer against short-term obligations. Profitability metrics show a return on equity of 7.77% and a return on assets of 1.79%, which are below the typical thresholds for high-performing firms in the Drug Retailers industry. The company's operating income of 2.39 billion JPY and net income of 1.26 billion JPY indicate a relatively narrow margin structure, with a gross profit of 50.74 billion JPY. These figures suggest that the company is not outperforming the industry median in terms of profitability. The company's revenue is distributed across five segments: Pharmaceutical Product Network, Dispensing Pharmacy, Leasing and Equipment-related Business, Food Supply, and Others. The Dispensing Pharmacy and Pharmaceutical Product Network segments are likely the primary contributors to revenue, though the exact distribution is not disclosed. The company's geographic exposure is not specified, but its operations are concentrated in Japan, as indicated by the JPY financials. The company's growth trajectory is modest, with no specific numeric deltas provided for the current or next fiscal year. Historical revenue of 122.39 billion JPY suggests a stable but not rapidly growing business. The company's capital expenditure of -3.09 billion JPY indicates a net outflow, which may reflect investments in infrastructure or expansion. The company faces a medium liquidity risk, as noted in the risk assessment, and a key flag is the negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential reported. The company's risk assessment does not indicate any major regulatory or geopolitical risks, but the high debt-to-equity ratio suggests a need for careful monitoring of leverage. Recent events include the latest actual EPS of 43.18 JPY and actual revenue of 122.39 billion JPY, as reported by analysts. No recent filings or transcripts are provided in the input data, so the narrative is based on the latest financial snapshot and valuation metrics.